CWRU grants exclusive license to Ionis Pharmaceuticals to advance therapy for rare childhood disorder
Crain’s Cleveland Business(subscription required): Paul Tesar, the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics at the School of Medicine, discussed a new exclusive license agreement with Ionis Pharmaceuticals Inc. to advance and commercialize a therapeutic approach that university medical researchers discovered to treat a rare childhood degenerative disorder called Pelizaeus-Merzbacher disease (PMD).